Limited Spending: An Analysis of Correctional Expenditures on Antiretrovirals for HIV-Infected Prisoners

Objective. Correctional facilities provide a critical opportunity to treat and manage human immunodeficiency virus (HIV) and HIV-related complications among inmates. Inmates bear a higher HIV burden than the general population, and many have never received HIV care prior to incarceration. The standard of care in the community and in corrections for the treatment of HIV is highly active antiretroviral therapy (HAART). This study evaluated U.S. correctional expenditures for antiretrovirals (ARVs) and compared them to the estimated need for ARVs among HIV-infected prisoners in the U.S. to treat this population successfully. Methods. The total number of HIV-infected prisoners in the United States was estimated using Bureau of Justice Statistics data. The National Sales Perspectives Audit, Combined Retail and Nonretail, July 1999 to December 2004 was used to estimate correctional ARV expenditures in 2004. Both measures were used to calculate treatment costs for ARV therapy. Results. The analysis demonstrates that, in 2004, total ARV sales represented only 29% of the total necessary to treat all HAART eligible inmates with known HIV infection. Conclusion. There is a substantial unmet need for ARVs in correctional health care. Although many barriers exist to treating all eligible HIV-infected prisoners, treatment reduces costs associated with HIV-related complications and may encourage linkage to HIV care in the community. Treatment of all eligible HIV-infected inmates should be a public health priority.

[1]  Jerome H. Carter,et al.  Distribution of health care expenditures for HIV-infected patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  T. Conklin,et al.  Facilitators and Barriers to Continuing Healthcare After Jail: A Community‐integrated Program , 2006, The Journal of ambulatory care management.

[3]  J. Vertefeuille,et al.  Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities , 2004, Journal of Urban Health.

[4]  J. Rich,et al.  Successful linkage of medical care and community services for HIV-positive offenders being released from prison , 2001, Journal of Urban Health.

[5]  F. Altice,et al.  Managing HIV/AIDS in correctional settings , 2005, Current HIV/AIDS reports.

[6]  J. Kaldor,et al.  Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. , 2005, Addiction.

[7]  D. J. James,et al.  Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002: (482222006-001) , 2005 .

[8]  D. Vlahov,et al.  Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. , 2004, American journal of public health.

[9]  R. Hogg,et al.  Initiating Highly Active Antiretroviral Therapy and Continuity of HIV Care: The Impact of Incarceration and Prison Release on Adherence and HIV Treatment Outcomes , 2003, Antiviral therapy.

[10]  N. Freudenberg Adverse effects of US jail and prison policies on the health and well-being of women of color. , 2002, American journal of public health.

[11]  W. Rhodes,et al.  The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. , 2002, American journal of public health.

[12]  Melanie J. Simmons,et al.  Intraprison HIV transmission: an assessment of whether it occurs, how it occurs, and who is at risk. , 2002, AIDS education and prevention : official publication of the International Society for AIDS Education.

[13]  A. Spaulding,et al.  Human immunodeficiency virus in correctional facilities: a review. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Hammett,et al.  A collaborative effort to enhance HIV/STI screening in five county jails. , 2001, Public health reports.

[15]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[16]  M. Wong HIV Care in Correctional Settings Is Cost-Effective and Improves Medical Outcomes , 2001 .

[17]  J. Fleishman,et al.  Estimating the National Cost of Treating People With HIV Disease: Patient, Payer, and Provider Data , 2000, Journal of acquired immune deficiency syndromes.

[18]  L. Frank Prisons and public health: emerging issues in HIV treatment adherence. , 1999, The Journal of the Association of Nurses in AIDS Care : JANAC.

[19]  D. McCaffrey,et al.  The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. , 1998, The New England journal of medicine.

[20]  J. Wrench,et al.  Outbreak of HIV infection in a Scottish prison , 1995, BMJ.

[21]  R. Greifinger,et al.  Correctional Health Care: A Public Health Opportunity , 1993, Annals of Internal Medicine.

[22]  D. Vlahov,et al.  Prevalence of antibody to HIV-1 among entrants to US correctional facilities. , 1991, JAMA.

[23]  D. Vlahov,et al.  Transmission of HIV-1 within a statewide prison system. , 1988, AIDS.